PharmaCyte Biotech, Inc. (PMCB)

2,0050 +0,0250 (+1,26%) Alla chiusura: 03:58PM EDT

PharmaCyte Biotech, Inc.

3960 Howard Hughes Parkway
Suite 500
Las Vegas, NV 89169
United States
917 595 2850
https://pharmacyte.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 2

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Joshua N. Silverman	Interim CEO, President & Director	197,92k	N/D	1970
Mr. Carlos A. Trujillo CPA, CPA	Chief Financial Officer	380k	N/D	1958
Dr. Jose L. Iglesias M.D.	Consulting Chief Medical Officer	N/D	N/D	1957
Dr. Hans-Peter Hammes	Member of Medical & Scientific Advisory Board and Consultant	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Governance aziendale

L'ISS Governance QualityScore di PharmaCyte Biotech, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.